Latest Regulatory Milestones News

Alligator Energy reports significant progress across its uranium portfolio, including regulatory milestones at Samphire and promising drilling results at Big Lake and Nabarlek North, supported by a solid cash position of $20.2 million.

Triton Minerals has secured A$17 million from the sale of a 70% stake in its Mozambique graphite assets, while progressing environmental approvals and unveiling promising high-grade gold and copper results at its new Aucu project.

Echo IQ confirms the material significance of its pre-submission FDA meeting for EchoSolv HF, marking a pivotal step toward US market entry and commercialisation.

Cambium Bio has secured a A$3 million capital raise and achieved FDA Fast Track status for its lead ophthalmology product, Elate Ocular®, setting the stage for Phase 3 trials in mid-2025.

Kaili Resources has streamlined its exploration portfolio by divesting high-cost, low-return tenements and is intensifying efforts in rare earths and precious metals exploration, targeting promising projects in South Australia and Western Australia.

Emyria Limited reports strong progress in its MDMA and psilocybin-assisted therapy programs alongside a successful $2.525 million capital raise, positioning the company for expanded mental health treatment services.

Ark Mines has delivered a significant upgrade to its Sandy Mitchell Rare Earths Project, including a new Mineral Resource Estimate and a completed Scoping Study confirming commercial viability. The company is now preparing for a Pre-Feasibility Study to expand resources and refine project economics.

Clarity Pharmaceuticals reports robust progress in its SECURE trial and secures FDA Fast Track Designation for its diagnostic agent 64Cu-SAR-bisPSMA, underpinning its growth and innovation in prostate cancer treatment.

Structural Monitoring Systems plc has raised $8.7 million and implemented a major cost restructuring, positioning itself for profitable growth with strong sales momentum in its avionics and sensor technology segments.

Opthea Limited reports steady progress in its Phase 3 trials for sozinibercept, a novel treatment for wet AMD, supported by a strong cash position and a recent R&D tax incentive.

Prescient Therapeutics has secured FDA clearance to initiate its Phase 2 PTX-100 trial for relapsed cutaneous T-cell lymphoma, alongside progress in its cell therapy platforms and a solid cash position bolstered by a recent R&D rebate.

Titanium Sands Limited has made significant progress in securing its Industrial Mining License for the Mannar Project in Sri Lanka, while preparing for a crucial funding placement to support ongoing development.